AR061668A1 - Jarabes antihistaminicos, estables al almacenamiento, sin azucar - Google Patents

Jarabes antihistaminicos, estables al almacenamiento, sin azucar

Info

Publication number
AR061668A1
AR061668A1 ARP070102860A ARP070102860A AR061668A1 AR 061668 A1 AR061668 A1 AR 061668A1 AR P070102860 A ARP070102860 A AR P070102860A AR P070102860 A ARP070102860 A AR P070102860A AR 061668 A1 AR061668 A1 AR 061668A1
Authority
AR
Argentina
Prior art keywords
formulation
stable
storage
antihistamine syrup
antihistamine
Prior art date
Application number
ARP070102860A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR061668A1 publication Critical patent/AR061668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Una formulacion de jarabe antihistamínico cuyos ingredientes comprenden loratadina, desloratadina o una sal farmacéuticamente aceptable de ellas o una combinacion de dos o más de las mismas, propilenglicol, sorbitol, citrato de sodio dihidrato, ácido cítrico anhidro, povidona, sucralosa, opcionalmente benzoato de sodio y opcionalmente ácido aminopolicarboxílico o una sal de éste, en la cual la formulacion de jarabe antihistamínico tiene un pH de más de 4,5; siendo dicha formulacion de jarabe antihistamínico estable al almacenamiento. Reivindicacion 19: El uso de la formulacion de jarabe antihistamínico de la afirmacion 1 u 11 para la fabricacion de un medicamento para el tratamiento y/o la prevencion de afecciones alérgicas e inflamatorias de la piel o las vías respiratorias en seres humanos que lo necesitan.
ARP070102860A 2006-06-29 2007-06-27 Jarabes antihistaminicos, estables al almacenamiento, sin azucar AR061668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81731206P 2006-06-29 2006-06-29

Publications (1)

Publication Number Publication Date
AR061668A1 true AR061668A1 (es) 2008-09-10

Family

ID=38739452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102860A AR061668A1 (es) 2006-06-29 2007-06-27 Jarabes antihistaminicos, estables al almacenamiento, sin azucar

Country Status (18)

Country Link
US (1) US20080262017A1 (es)
EP (1) EP2037921A2 (es)
JP (1) JP2009542665A (es)
KR (1) KR20090024282A (es)
CN (1) CN101505750A (es)
AR (1) AR061668A1 (es)
AU (1) AU2007269835A1 (es)
BR (1) BRPI0713933A2 (es)
CA (1) CA2656087A1 (es)
CL (1) CL2007001913A1 (es)
CO (1) CO6230988A2 (es)
MX (1) MX2009000121A (es)
NO (1) NO20090458L (es)
PE (1) PE20080994A1 (es)
SG (1) SG173333A1 (es)
TW (1) TW200808374A (es)
WO (1) WO2008005267A2 (es)
ZA (1) ZA200900168B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101548959B (zh) * 2008-04-03 2012-11-21 万特制药(海南)有限公司 一种含有地氯雷他定的包衣片剂及其制备方法
WO2011146030A2 (en) * 2010-05-18 2011-11-24 Mahmut Bilgic Effervescent antihistamine formulations
MX346879B (es) 2010-10-21 2017-04-03 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para su uso.
WO2013062497A1 (en) * 2011-10-13 2013-05-02 Mahmut Bilgic Liquid pharmaceutical formulations
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
CN104434789B (zh) * 2014-12-27 2017-04-26 昆明振华制药厂有限公司 一种枸橼酸喷托维林糖浆的制备方法
KR102242382B1 (ko) * 2020-02-28 2021-04-20 삼익제약주식회사 용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물
CN113081958B (zh) * 2021-05-01 2022-05-03 安徽新世纪药业有限公司 一种地氯雷他定口服溶液及其制备方法
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
CN114767677B (zh) * 2022-05-06 2023-11-07 成都倍特药业股份有限公司 一种氯雷他定组合物及其制备方法
CN115475141A (zh) * 2022-10-14 2022-12-16 漳州片仔癀药业股份有限公司 一种地氯雷他定口服溶液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
PA8517201A1 (es) * 2000-05-25 2002-08-26 Schering Corp Composiciones farmaceuticas antihistaminicas anticongestivas liquidas estables
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US7758877B2 (en) * 2004-02-05 2010-07-20 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation

Also Published As

Publication number Publication date
CO6230988A2 (es) 2010-12-20
WO2008005267A3 (en) 2008-07-10
NO20090458L (no) 2009-01-28
ZA200900168B (en) 2010-06-30
CL2007001913A1 (es) 2008-01-11
AU2007269835A1 (en) 2008-01-10
CN101505750A (zh) 2009-08-12
PE20080994A1 (es) 2008-08-06
JP2009542665A (ja) 2009-12-03
US20080262017A1 (en) 2008-10-23
KR20090024282A (ko) 2009-03-06
SG173333A1 (en) 2011-08-29
MX2009000121A (es) 2009-01-26
EP2037921A2 (en) 2009-03-25
BRPI0713933A2 (pt) 2012-12-18
CA2656087A1 (en) 2008-01-10
TW200808374A (en) 2008-02-16
WO2008005267A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
UY32599A (es) Formulación oral sólida de abt-263
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
ECSP088165A (es) Formulaciones liquidas
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
AR058133A1 (es) Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
MY146988A (en) Fexofenadine suspension formulation
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
GT200600263A (es) Regimen de dosificacion para prasugrel
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
FR2898271A1 (fr) Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
RU2006131594A (ru) Гликозидное пролекарство 5-аминосалициловой кислоты
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
JP2007504194A5 (es)
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
CL2008002025A1 (es) Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal